Yes, SARS-CoV-2 will continue to mutate for as long as it circulates in the human population. It has already produced dozens of named variants since 2020, and new lineages continue to emerge. The virus mutates more slowly than influenza, roughly five times slower by evolutionary rate, but it has other tricks that keep it changing fast enough to cause new waves of infection.
Why the Virus Keeps Changing
SARS-CoV-2 is an RNA virus, and RNA viruses are inherently error-prone when they copy their genetic material. Every time the virus replicates inside a human cell, its copying machinery introduces small mistakes into the genetic code. Most of these mistakes are harmless or even harmful to the virus. But occasionally, a random error gives the virus an advantage, like better attachment to human cells or the ability to slip past antibodies. That version then outcompetes the others and spreads.
Coronaviruses do have a built-in proofreading enzyme that catches some of these copying errors, which is unusual among RNA viruses. This is partly why SARS-CoV-2 mutates at a rate of roughly 0.8 to 1.1 changes per thousand genetic positions per year in its spike gene, compared to about 4.8 per thousand for influenza’s main surface gene. That proofreading slows things down but doesn’t stop evolution entirely.
What Drives Mutations to Spread
Random errors alone don’t shape the virus’s future. The mutations that take over are the ones selected by pressure from the environment, and in this case, the biggest pressure is human immunity. As billions of people have been infected, vaccinated, or both, the virus faces a wall of antibodies. Mutations that help the virus dodge those antibodies have a survival advantage.
Research published in Molecular Ecology found that the regions of the spike and nucleocapsid proteins targeted by antibodies show significantly higher genetic diversity than non-targeted regions. In other words, the parts of the virus that your immune system recognizes most strongly are exactly the parts that mutate most. Interestingly, the regions recognized by T cells (another branch of the immune system) remain much more conserved. The virus appears to evolve primarily to escape antibody responses, not T cell responses, which is one reason T cell immunity tends to hold up better over time against new variants.
Convergent Evolution Creates Familiar Patterns
One of the most striking patterns in SARS-CoV-2 evolution is convergent evolution, where completely unrelated viral lineages independently land on the same mutations. During the first two years of the pandemic, variants of concern kept arriving at changes at positions K417, L452, E484, N501, and P681 on the spike protein. Alpha, Beta, Gamma, and Delta all hit some of these same spots through separate evolutionary paths.
Since Omicron took over in 2022, a new set of hotspots emerged: positions R346, K444, N450, N460, F486, F490, Q493, and S494. Multiple Omicron sublineages converged on these same changes independently. This isn’t coincidence. These positions sit in the part of the spike protein that antibodies bind to most effectively, so mutations there offer the biggest payoff for immune evasion. It also means scientists can partially anticipate where the next mutations will land, even if they can’t predict the exact timing or combination.
Recombination Adds Another Layer
Mutation isn’t the only way SARS-CoV-2 changes. When two different variants infect the same person at the same time, the virus can swap large chunks of genetic material between them, a process called recombination. The virus’s copying machinery detaches from one RNA template mid-copy and picks up on a different one, stitching together a hybrid genome.
This has already happened many times. Dozens of recombinant lineages have been formally catalogued. XD combined Delta with the Omicron spike protein. XE was a hybrid of two Omicron sublineages, BA.1 and BA.2, and at one point showed a growth advantage of about 10% per week over BA.2. As of early 2026, the XFG lineage and its descendants had been detected in 97 countries, with over 81,000 genome sequences shared globally. Recombination can produce large evolutionary jumps in a single step, rather than the slow accumulation of point mutations.
How Mutations Affect Vaccines
Each new round of mutations chips away at how well existing antibodies neutralize the virus. This has been documented repeatedly. The Beta variant reduced neutralization by Pfizer vaccine sera by 3.4 to 7.6-fold. It also showed reduced neutralization against sera from Moderna and AstraZeneca vaccinated individuals. The E484K mutation, found in several early variants, became known as a key immune escape mutation because it sits right in the antibody binding site on the spike protein.
This is why COVID vaccines need periodic updates, similar to the annual flu shot. The good news is that even when antibody neutralization drops against a new variant, T cell responses tend to hold up because the virus doesn’t easily escape T cell recognition. This means vaccines may become less effective at preventing infection with each new variant, but they continue to offer meaningful protection against severe illness. Some spike mutations also weaken the interaction between viral proteins and T cells, at positions like K417, L452, and Y144, but this kind of T cell evasion is far less common than antibody evasion.
Antiviral Resistance Is Emerging
Mutations don’t just affect vaccines. The virus is also beginning to evolve resistance to antiviral drugs. Several mutations in the viral protease, the enzyme targeted by treatments like Paxlovid, have been identified under drug selection pressure. Some mutations, including S144A, E166A, and L167F, confer resistance to multiple antiviral drugs simultaneously.
The picture is complicated, though. A recent study published in Nature Communications found a deletion mutation that made the virus highly resistant to one protease inhibitor (about 35-fold reduction in drug effectiveness) while paradoxically making it eight times more susceptible to another. This suggests the two drugs have different enough mechanisms that resistance to one doesn’t automatically mean resistance to both, which has practical implications for how doctors might sequence or combine treatments in the future.
How This Compares to Influenza
People often ask whether SARS-CoV-2 will become “like the flu.” In terms of raw mutation speed, influenza evolves about five times faster in its key surface genes. Flu also has a segmented genome, meaning it can reassort entire gene segments when two strains co-infect, which is how pandemic flu strains have historically emerged. SARS-CoV-2 can’t do this because its genome is a single continuous strand.
However, SARS-CoV-2 compensates with a very large population size (billions of infections provide enormous opportunities for rare mutations to arise), recombination between co-circulating lineages, and strong immune selection pressure from a largely pre-exposed global population. The result is a virus that, despite mutating more slowly per replication cycle than flu, still generates enough variation to produce new immune-evasive waves roughly every several months. The pattern of periodic variant emergence and updated vaccines is likely to continue for the foreseeable future, much as it does with seasonal influenza.